204 related articles for article (PubMed ID: 8156491)
1. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma.
Casper ES; Gaynor JJ; Harrison LB; Panicek DM; Hajdu SI; Brennan MF
Cancer; 1994 Mar; 73(6):1644-51. PubMed ID: 8156491
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
[TBL] [Abstract][Full Text] [Related]
3. [Pilot study of an alternative CYVADIC + CBDCA protocol for adult soft tissue sarcoma as adjuvant chemotherapy].
Matsumoto S; Kawaguchi N; Manabe J; Matsushita Y; Tanizawa T
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1571-4. PubMed ID: 12355942
[TBL] [Abstract][Full Text] [Related]
4. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
Hempling RE; Piver MS; Baker TR
Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.
Kraybill WG; Harris J; Spiro IJ; Ettinger DS; DeLaney TF; Blum RH; Lucas DR; Harmon DC; Letson GD; Eisenberg B;
J Clin Oncol; 2006 Feb; 24(4):619-25. PubMed ID: 16446334
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
[TBL] [Abstract][Full Text] [Related]
7. Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma.
Tsuchiya H; Tomita K; Yamamoto N; Mori Y; Asada N
Anticancer Res; 1998; 18(5B):3651-6. PubMed ID: 9854472
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
DeLaney TF; Spiro IJ; Suit HD; Gebhardt MC; Hornicek FJ; Mankin HJ; Rosenberg AL; Rosenthal DI; Miryousefi F; Ancukiewicz M; Harmon DC
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1117-27. PubMed ID: 12829150
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
11. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma.
Gortzak E; Azzarelli A; Buesa J; Bramwell VH; van Coevorden F; van Geel AN; Ezzat A; Santoro A; Oosterhuis JW; van Glabbeke M; Kirkpatrick A; Verweij J;
Eur J Cancer; 2001 Jun; 37(9):1096-103. PubMed ID: 11378339
[TBL] [Abstract][Full Text] [Related]
12. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
13. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
14. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
Bramwell V; Quirt I; Warr D; Verma S; Young V; Knowling M; Eisenhauer E
J Natl Cancer Inst; 1989 Oct; 81(19):1496-9. PubMed ID: 2778839
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.
Woll PJ; Reichardt P; Le Cesne A; Bonvalot S; Azzarelli A; Hoekstra HJ; Leahy M; Van Coevorden F; Verweij J; Hogendoorn PC; Ouali M; Marreaud S; Bramwell VH; Hohenberger P;
Lancet Oncol; 2012 Oct; 13(10):1045-54. PubMed ID: 22954508
[TBL] [Abstract][Full Text] [Related]
17. Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma.
Tsuchiya H; Yamamoto N; Asada N; Terasaki T; Kanazawa Y; Takanaka T; Nishijima H; Tomita K
Anticancer Res; 2000; 20(3B):2137-43. PubMed ID: 10928167
[TBL] [Abstract][Full Text] [Related]
18. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]